Hypertrophic ScarNCT05771623
Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar
A study testing Iontophoresis drug delivery device and Traditional physical therapy in people with Hypertrophic Scar, run by Cairo University at 1 site in Egypt.
Trial summary
The goal of this clinical trial study: is to determine the effect Botulinum toxin type A iontophoresis in hypertrophic scars for post burned patients. The main question is it aims to answer is: Does Botulinum toxin type A iontophoresis may help in minimizing postburn hypertrophic scars? Participants will receive the… Read more about this study
- Who is it for?
- Ages 20 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypertrophic Scar
- What is being tested?
- Iontophoresis drug delivery device and Traditional physical therapy
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 76 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Aug 2022to Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Patient with hypertrophic scar (3-6) months after burn healing.
- Age range between 20-40 years.
- Male and female patients will participate in the study.
- All patients have a postburn hypertrophic scar at different body sites.
- All patients enrolled on the study will have their informed consent.
Who cannot join
- Patients with prior medical histories of cardiac arrhythmias.
- Patients with cardiac pacemakers.
- Patients with orthopedic implants.
- Areas of skin with lesions and impaired sensation.
- During pregnancy and breastfeeding.
- Patient with diabetes mellitus.
Show all 9Show fewer
- Patients with a history of hypersensitivity or adverse reactions associated with (BTX_A).
- Recent BTA administration 6 months before the study.
- Any subject complaining of psychiatric disorders or neurological disorders such as myasthenia gravis.
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Faculty of physical therapy
Giza, Dokki, 11432
A M Abd Elbaky, Professor, +201124663339, amalabaky@yahoo.com
N H Aboelnour, A. Professor, Telephone: 01068904389
About this study
The goal of this clinical trial study: is to determine the effect Botulinum toxin type A iontophoresis in hypertrophic scars for post burned patients. The main question is it aims to answer is:
- Does Botulinum toxin type A iontophoresis may help in minimizing postburn hypertrophic scars?
- Participants will receive the treatment for 3 months.
- Assessment will be done before and after treatment.
Read the detailed description
- Subjects: Seventy-six Patients from both genders who have post burn hypertrophic scar will participate in this study. Their ages will be ranged 20 to 40 years.
- Design of the study:
In this study the patients will be randomly assigned into two equal groups (38 patients for each group):
- Group A (Study group): This group includes 38 patients who will receive botulinum toxin type A iontophoresis once monthly for 3 months, in additional to traditional physical therapy (Positioning, Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.
- Group B (Control group): This group includes 38 patients who will receive traditional physical therapy (Positioning, Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.
- Equipments: Measurement equipments:
- Sonography: It is high-resolution B-image sonogram which allows a good penetration depth of up to 40 mm into the skin and a resolution of around 158 micro m. It has been successfully utilized for objectively measuring pathological scars.
- Patient and Observer Scar Assessment Scale (POSAS): It consists of two parts; one for the patient (Patient scale; POSAS Patient) and one for the physician (Observer scale; POSAS Observer). Both contain six items on a 10-point rating scale and an extra category "Overall Opinion". All characteristic features of the pathological scars are covered by the questionnaire: vascularity, pigmentation disorders, relief/texture, thickness, pliability, surface area, pain, and itching/pruritus. The latter items, in particular, concern the well-being of the patients.
- Sonography:
- High frequency ultrasound is the most common used technique for scar assessment.
- The working mechanism is based on refection of sound waves of structures with different acoustic impedances and the analysis of the refection time to determine the depth of the structure.
- The penetration depth ranges from the upper dermal layers to full-thickness skin and subcutaneous structures, depending on the employed frequency b. Patient and Observer scar Assessment Scale (POSAS):
- The scar will be rated numerically on a ten-step scale by both the patient and doctor.
- Six items on the Observer Scale: vascularity, pigmentation, thickness, relief, pliability, and surface area.
- The Patient Scale consists of pain, itchiness, color, stiffness, thickness, and irregularity of the scar.
- One of the reasons POSAS was chosen for scar evaluation is because it is the only scar assessment tool to include a component for patients to fill in.
- Furthermore, its distinctive feature of reflecting subjective symptoms like pain and pruritus and because of its appropriateness for everyday practice.
- Both sonography and POSAS will be used for assessment of hypertrophic scar pre-treatment and post treatment (after 3 months then after 6 months as follow up).
- Procedures of iontophoresis drug delivery device: the iontophoresis group will receive botulinum toxin type A iontophoresis using an iontophoretic drug delivery system (Phoresor IIAuto,Model PM850, IOMED.) - Procedures of botulinum toxin type A iontophoresis:
- Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) will be used.
- 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) will be administered once a month for a total period of three months.
- The dose will be adjusted to 2.5 U/cm2 of the lesion.
- The dose shouldn't exceed 100 units per session.
- Physical therapy program for both groups: traditional physical therapy (Positioning, Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months
- Conditions
- Hypertrophic Scar
- Being tested
- Iontophoresis drug delivery device, Traditional physical therapy
- Keywords
- Hypertrophic scar
- Medical subject headings
- Cicatrix, Hypertrophic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Iontophoresis drug delivery deviceDevice
Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.
The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.
This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).
Traditional physical therapyBehavioural
Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).
| Study group | Role | What they receive |
|---|---|---|
| Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar | Experimental | The study group includes 38 postburn hypertrophic scar patients l receiving Botox iontophoresis once monthly for 3 months; in addition to their physical therapy program (Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.
Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.
The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session. Receives: Device: Iontophoresis drug delivery device; Behavioral: Traditional physical therapy |
| Traditional physical therapy for postburn hypertrophic scar | Active comparator | This group includes 38 patients with postburn hypertrophic scar who will receive the traditional PT (deep friction massage, stretching and pressure therapy). Receives: Behavioral: Traditional physical therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
High resoluton ultrasonography
High frequency ultrasound is the most common used technique for scar assessment. Its inferior resolution compared to optical equivalents is mitigated by its superior penetration depth allowing thickness analysis, even in severe scar thickening. The working mechanism is based on refection of sound waves of structures with different acoustic impedances and the analysis of the refection time to determine the depth of the structure. The penetration depth ranges from the upper dermal layers to full-thickness skin and subcutaneous structures, depending on the employed frequency.
Measured: Change of hypertrophic scar thickness from the beginning of treatment to the end of treatment(after 3 months from the beginning of treatment).
Patient and observer scar assessment scale
The scar will be rated numerically on a ten-step scale by both the patient and doctor on six items: vascularity, pigmentation, thickness, relief, pliability, and surface area on the Observer Scale. The Patient Scale consists of pain, itchiness, color, stiffness, thickness, and irregularity of the scar. Minimal score means good progression and maximum score means the scare is worse.
Measured: Assessing the change of patient and observer scar assessment scale score from baseline (beginning of treatment) to 3 months after treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2023
- Study start1 Aug 2022
- Primary completionDec 2023 (estimated)
- Study completionDec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypertrophic ScarStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Control group: (38 patients with hypertrophic scar) receive traditional PT for postburn scar. Study group: (38 patients with hypertrophic scar) receive botulinum toxin type a iontophoresis plus traditional PT.
- Masking
- None (open label)
- Enrolment
- 76 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hayam Mahmoud Aboulmaati Alnawagy, Cairo University
- Investigators
- A M Abd Elbaky, Professor, Study director, faculty of physical therapy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05771623
- Sponsor's protocol ID
- P.T.REC/012/003749
- Status last verified
- Jun 2023
- First submitted
- 14 Feb 2023
- Last updated
- 6 Jun 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar
- ClinicalTrials.gov ID
- NCT05771623
- Acronym / sponsor ID
- P.T.REC/012/003749
- Conditions
- Hypertrophic Scar
- Keywords
- Hypertrophic scar
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 76 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Aug 2022 (actual)
- Primary completion
- Dec 2023 (estimated)
- Study completion
- Dec 2023 (estimated)
- First posted
- 16 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial study: is to determine the effect Botulinum toxin type A iontophoresis in hypertrophic scars for post burned patients. The main question is it aims to answer is:
- Does Botulinum toxin type A iontophoresis may help in minimizing postburn hypertrophic scars?
- Participants will receive the treatment for 3 months.
- Assessment will be done before and after treatment.
Detailed description
- Subjects: Seventy-six Patients from both genders who have post burn hypertrophic scar will participate in this study. Their ages will be ranged 20 to 40 years.
- Design of the study:
In this study the patients will be randomly assigned into two equal groups (38 patients for each group):
- Group A (Study group): This group includes 38 patients who will receive botulinum toxin type A iontophoresis once monthly for 3 months, in additional to traditional physical therapy (Positioning, Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.
- Group B (Control group): This group includes 38 patients who will receive traditional physical therapy (Positioning, Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.
- Equipments: Measurement equipments:
- Sonography: It is high-resolution B-image sonogram which allows a good penetration depth of up to 40 mm into the skin and a resolution of around 158 micro m. It has been successfully utilized for objectively measuring pathological scars.
- Patient and Observer Scar Assessment Scale (POSAS): It consists of two parts; one for the patient (Patient scale; POSAS Patient) and one for the physician (Observer scale; POSAS Observer). Both contain six items on a 10-point rating scale and an extra category "Overall Opinion". All characteristic features of the pathological scars are covered by the questionnaire: vascularity, pigmentation disorders, relief/texture, thickness, pliability, surface area, pain, and itching/pruritus. The latter items, in particular, concern the well-being of the patients.
- Sonography:
- High frequency ultrasound is the most common used technique for scar assessment.
- The working mechanism is based on refection of sound waves of structures with different acoustic impedances and the analysis of the refection time to determine the depth of the structure.
- The penetration depth ranges from the upper dermal layers to full-thickness skin and subcutaneous structures, depending on the employed frequency b. Patient and Observer scar Assessment Scale (POSAS):
- The scar will be rated numerically on a ten-step scale by both the patient and doctor.
- Six items on the Observer Scale: vascularity, pigmentation, thickness, relief, pliability, and surface area.
- The Patient Scale consists of pain, itchiness, color, stiffness, thickness, and irregularity of the scar.
- One of the reasons POSAS was chosen for scar evaluation is because it is the only scar assessment tool to include a component for patients to fill in.
- Furthermore, its distinctive feature of reflecting subjective symptoms like pain and pruritus and because of its appropriateness for everyday practice.
- Both sonography and POSAS will be used for assessment of hypertrophic scar pre-treatment and post treatment (after 3 months then after 6 months as follow up).
- Procedures of iontophoresis drug delivery device: the iontophoresis group will receive botulinum toxin type A iontophoresis using an iontophoretic drug delivery system (Phoresor IIAuto,Model PM850, IOMED.) - Procedures of botulinum toxin type A iontophoresis:
- Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) will be used.
- 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) will be administered once a month for a total period of three months.
- The dose will be adjusted to 2.5 U/cm2 of the lesion.
- The dose shouldn't exceed 100 units per session.
- Physical therapy program for both groups: traditional physical therapy (Positioning, Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Control group: (38 patients with hypertrophic scar) receive traditional PT for postburn scar. Study group: (38 patients with hypertrophic scar) receive botulinum toxin type a iontophoresis plus traditional PT.
| Arm | Type | Receives |
|---|---|---|
| Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar | Experimental | Device: Iontophoresis drug delivery device, Behavioral: Traditional physical therapyThe study group includes 38 postburn hypertrophic scar patients l receiving Botox iontophoresis once monthly for 3 months; in addition to their physical therapy program (Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months. Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months. The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session. |
| Traditional physical therapy for postburn hypertrophic scar | Active comparator | Behavioral: Traditional physical therapyThis group includes 38 patients with postburn hypertrophic scar who will receive the traditional PT (deep friction massage, stretching and pressure therapy). |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Patient with hypertrophic scar (3-6) months after burn healing.
- Age range between 20-40 years.
- Male and female patients will participate in the study.
- All patients have a postburn hypertrophic scar at different body sites.
- All patients enrolled on the study will have their informed consent.
Key exclusion criteria (9 listed)
- Patients with prior medical histories of cardiac arrhythmias.
- Patients with cardiac pacemakers.
- Patients with orthopedic implants.
- Areas of skin with lesions and impaired sensation.
- During pregnancy and breastfeeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Iontophoresis drug delivery deviceBotulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months. The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session. This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months). | Device | Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar |
| Traditional physical therapyTraditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months). | Behavioural | Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar, Traditional physical therapy for postburn hypertrophic scar |
Primary outcome
High resoluton ultrasonography
Time frame: Change of hypertrophic scar thickness from the beginning of treatment to the end of treatment(after 3 months from the beginning of treatment).
High frequency ultrasound is the most common used technique for scar assessment. Its inferior resolution compared to optical equivalents is mitigated by its superior penetration depth allowing thickness analysis, even in severe scar thickening. The working mechanism is based on refection of sound waves of structures with different acoustic impedances and the analysis of the refection time to determine the depth of the structure. The penetration depth ranges from the upper dermal layers to full-thickness skin and subcutaneous structures, depending on the employed frequency.
Patient and observer scar assessment scale
Time frame: Assessing the change of patient and observer scar assessment scale score from baseline (beginning of treatment) to 3 months after treatment.
The scar will be rated numerically on a ten-step scale by both the patient and doctor on six items: vascularity, pigmentation, thickness, relief, pliability, and surface area on the Observer Scale. The Patient Scale consists of pain, itchiness, color, stiffness, thickness, and irregularity of the scar. Minimal score means good progression and maximum score means the scare is worse.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2023.
- Individual participant dataSharing planned: No
Related trials for Hypertrophic Scar
Not yet recruitingObservational study
Hypertrophic Scar Prosthetic Pressure in Burn Amputee
Amputation Stump, Burn Injury
Not yet recruitingPhase 2
Phase II Clinical Study on Preliminary Efficacy and Safety of ETD-001 Gel for Hypertrophic Scars
Hypertrophic Scars
Not yet recruiting
Surgical Dressing Study Comparing SYLKE vs Other Common Incisional Dressings Following Abdominoplasty/Panniculectomy Patients
Hypertrophic Surgical Scar, Medical Adhesive Related Skin Injury
Recruiting
Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color
Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation
Recruiting
AVAVA MIRIA General Use
Acne, Acne Scars - Mixed Atrophic and Hypertrophic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
A M Abd Elbaky, Professor study director
faculty of physical therapy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Iontophoresis drug delivery device and Traditional physical therapy in people with Hypertrophic Scar, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact H M Alnawagy, A lecturer (+201032733250, hayammahmoud120@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
High resoluton ultrasonography (time frame: Change of hypertrophic scar thickness from the beginning of treatment to the end of treatment(after 3 months from the beginning of treatment).). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2023.